Arca
Skip to content
Tools
Tools

Label Changes: Thalomid (thalidomide)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Thalomid label DailyMed has published, from Celgene Corporation, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 19
  • Sections changed, version 25 to 26: 11, Including the boxed warning

What changed from version 25 to version 26

Apr 6, 2023 to Oct 26, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningChanged · 3 words added, 3 removed
  2. Dosage and administrationChanged · 3 words added, 3 removed
  3. Warnings and precautionsChanged · 11 words added, 12 removed
  4. Adverse reactionsChanged · punctuation or symbols only
  5. DescriptionChanged · punctuation or symbols only
  6. Clinical pharmacologyChanged · 1 word added, 1 removed
  7. Clinical studiesChanged · punctuation or symbols only
  8. How suppliedChanged · 2 words added, 2 removed
  9. Patient counseling informationChanged · 5 words added, 5 removed
  10. Medication guideChanged · 53 words added, 55 removed
  11. Untitled sectionChanged · 5 words added, 7 removed

Boxed warning

Changed3 words added, 3 removed
2 unchanged lines
If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could become pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects.
Because of this toxicity and in an effort to make the chance of embryo-fetal exposure to THALOMID as negligible as possible, THALOMID is approved for marketing only through a special restricted distribution program: THALOMIDThalidomide REMS program, approved by the Food and Drug Administration.
Information about THALOMID and the THALOMIDThalidomide REMS program is available at www.thalomidremsthalidomideremsprogram.com or by calling the REMS Call Center at 1-888-423-5436.
VENOUS THROMBOEMBOLISM
1 unchanged line

Dosage and administration

Changed3 words added, 3 removed
2 unchanged lines
Drug prescribing to females of reproductive potential is contingent upon initial and continued negative results of pregnancy testing [see Warnings and Precautions (5.1 and 5.2)].
THALOMID must only be administered in compliance with all of the terms outlined in the THALOMIDThalidomide REMS program. THALOMID may only be prescribed by prescribers certified with the THALOMIDThalidomide REMS program and may only be dispensed by pharmacists certified with the THALOMIDThalidomide REMS program.
2.2 Recommended Dosage for Multiple Myeloma
11 unchanged lines

Warnings and precautions

Changed11 words added, 12 removed
1 unchanged line
5.1 Embryo-Fetal Toxicity
THALOMID is a powerful human teratogen that induces a high frequency of severe and life-threatening birth defects, even after a single dose. Mortality at or shortly after birth has been reported in about 40% of infants. When there is no satisfactory alternative treatment, females of reproductive potential may be treated with THALOMID provided adequate precautions are taken to avoid pregnancy. THALOMID is only available through the THALOMIDThalidomide REMS program [see Warnings and Precautions (5.2)].
Oral ingestion is the only type of maternal THALOMID exposure known to result in drug-associated birth defects. There are no specific data available regarding the reproductive risks of cutaneous absorption or inhalation of THALOMID; however, females of reproductive potential should avoid contact with THALOMID Capsulescapsules. THALOMID Capsulescapsules should be stored in blister packs until ingestion. If there is contact with non-intact THALOMID capsules or the powder contents, the exposed area should be washed with soap and water.
If healthcare providers or other care giverscaregivers are exposed to body fluids from patients receiving THALOMID, the exposed area should be washed with soap and water. Appropriate precautions should be utilized, such as wearing gloves to prevent the potential cutaneous exposure to THALOMID.
Females of Reproductive Potential
6 unchanged lines
Patients must not donate blood during treatment with THALOMID and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to THALOMID.
5.2 THALOMIDThalidomide REMS Program
Because of the embryo-fetal risk [see Warnings and Precautions (5.1)], THALOMID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), the THALOMIDThalidomide REMS program.
Required components of the THALOMIDThalidomide REMS program include the following:
•Prescribers must be certified with the THALOMIDThalidomide REMS program by enrolling and complying with the REMS requirements.
•Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see Use in Specific Populations (8.3)] and males must comply with contraception requirements [see Use in Specific Populations (8.3)].
•Pharmacies must be certified with the THALOMIDThalidomide REMS program, must only dispense to patients who are authorized to receive THALOMID and comply with REMS requirements.
Further information about the THALOMIDThalidomide REMS program is available at www.thalomidremsthalidomideremsprogram.com or by telephone at 1-888-423-5436.
5.3 Venous and Arterial Thromboembolism
33 unchanged lines

Adverse reactions

Changedpunctuation or symbols only
19 unchanged lines
Adverse Reactions in Multiple Myeloma Controlled Clinical Trials
The safety analyses were conducted in two controlled clinical studies (Study 1 and Study 2). The safety analysis in Study 1 was conducted on 204 patients who received treatment. Table 1 lists the most common adverse reactions (≥ 10%). The most frequently reported adverse reactions were fatigue, hypocalcemia, edema, constipation, sensory neuropathy, dyspnea, muscle weakness, leukopenia, neutropenia, rash/desquamation, confusion, anorexia, nausea, anxiety/agitation, tremor, fever, weight loss, thrombosis/embolism, neuropathy-motor, weight gain, dizziness, and dry skin.
Twenty-three percent of patients (47/204) discontinued due to adverse reactions; 30% (31/102) from the THALOMID/dexamethasone arm and 16% (16/102) from the dexamethasone alone arm.
203 unchanged lines
Blood and Lymphatic: Decreased white blood cell counts including febrile neutropenia, changes in prothrombin time, pancytopenia, chronic myelogenous leukemia, nodular sclerosing Hodgkin's disease, erythroleukemia, lymphedema, lymphopenia.
Body as a Whole: Hangover effect.
Cardiovascular System: Sick sinus syndrome, EKG abnormalities, pulmonary hypertension.
9 unchanged lines
Skin and Appendages: Erythema multiforme, erythema nodosum, toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), purpura, petechiae.
Special Senses: Diplopia, nystagmus.

Description

Changedpunctuation or symbols only
2 unchanged lines
Chemical Structure of Thalidomide
Note: ∙• = asymmetric carbon atom
Thalidomide is an off-white to white, odorless, crystalline powder that is soluble at 25°C in dimethyl sulfoxide and sparingly soluble in water and ethanol. The glutarimide moiety contains a single asymmetric center and, therefore, may exist in either of two optically active forms designated S-(-) or R-(+). THALOMID is an equal mixture of the S-(-) and R-(+) forms and, therefore, has a net optical rotation of zero.
1 unchanged line

Clinical pharmacology

Changed1 word added, 1 removed
6 unchanged lines
Table 5: Pharmacokinetic Parameter Values for THALOMID Mean (%CV)
Population/ Single Dose | AUC0-∞ mcg∙•hr/mL | Cmax mcg/mL | Tmax (hrs) | Half-life (hrs)
Healthy Subjects (n=14)
18 unchanged lines
Pharmacokinetic Data in Special Populations
HIV-seropositive Subjects: There is no apparent significant difference in measured pharmacokinetic parameter values between healthy human subjects and HIV-seropositive subjects following single-dose administration of THALOMID Capsulescapsules.
Patients with Hansen's Disease: Analysis of data from a small study in Hansen's patients suggests that these patients, relative to healthy subjects, may have an increased bioavailability of THALOMID. The increase is reflected both in an increased area under the curve and in increased peak plasma levels. The clinical significance of this increase is unknown.
3 unchanged lines

Clinical studies

Changedpunctuation or symbols only
66 unchanged lines
| Thalidomide/Dexamethasone (N=235) | Placebo/Dexamethasone (N=235)
a The 95% confidence intervals about the median overall TTP, or median overall survival. CI: confidence interval; NR: not reached. b Based on a proportional hazards model comparing the hazard functions associated with treatment groups (thalidomide/dexamethasone: placebo/dexamethasone). c P-value based on the interim analysis was compared with the nominal significance level of 0.0027. Based on a one-sided unstratified log rank test of survival curve differences between treatment groups. d Disease response assessments were determined according to the Bladé criteria. Response is the highest assessment of response during the treatment phase of the study.
Time to Progression | |
2 unchanged lines
Hazard Ratio (95% CI)b | 0.43 (0.32, 0.58)
P-valuec | < 0.0001
Overall Survival | |
28 unchanged lines

How supplied

Changed2 words added, 2 removed
16 HOW SUPPLIED/STORAGE AND HANDLING
(THIS PRODUCT IS ONLY SUPPLIED TO PHARMACIES CERTIFIED IN THE THALOMIDTHALIDOMIDE REMS PROGRAM - See BOXED WARNING)
16.1 How Supplied
5 unchanged lines
This drug must not be repackaged.
Store at 20°C- 25°C (68°F -77°F); excursions permitted to 15-30º C (59-86º F). [See USP Controlled Room Temperature]. Protect from light.
16.3 Handling and Disposal
1 unchanged line
Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published1.
Rx only and only able to be prescribed and dispensed under the terms of the THALOMIDThalidomide REMS Restricted Distribution Program.

Patient counseling information

Changed5 words added, 5 removed
11 unchanged lines
•All patients must be instructed to not donate blood while taking THALOMID and for 4 weeks following discontinuation of THALOMID [see Warnings and Precautions (5.1)].
THALOMID REMS Program
Thalidomide REMS Program
Because of the risk of embryo-fetal toxicity, THALOMID is only available through a restricted program called the THALOMIDThalidomide REMS program [see Warnings and Precautions (5.2)].
•Patients must sign a Patient-Physician Agreement Form and comply with the requirements to receive THALOMID. In particular, females of reproductive potential must comply with the pregnancy testing, contraception requirements and participate in monthly telephone surveys. Males must comply with the contraception requirements [see Use in Specific Populations (8.3)].
•THALOMID is available only from pharmacies that are certified in THALOMIDThalidomide REMS program. Provide patients with the telephone number and website for information on how to obtain the product.
Pregnancy Exposure Registry
27 unchanged lines

Medication guide

Changed53 words added, 55 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: March 20239/2026
MEDICATION GUIDE THALOMID® (tha-lo-mid) (thalidomide) capsules
What is the most important information I should know about THALOMID? Before you begin taking THALOMID, you must read and agree to all of the instructions in the THALOMIDThalidomide REMS® program. For more information, call 1-888-423-5436 or go to www.thalomidremsthalidomideremsprogram.com. Before prescribing THALOMID, your healthcare provider will explain the THALOMIDThalidomide REMS program to you and have you sign the Patient-Physician Agreement Form. THALOMID can cause serious side effects including: • Severe and life-threatening human birth defects (deformed babies) or death of an unborn baby. Females who are pregnant or who plan to become pregnant must not take THALOMID. • Females must not get pregnant: oFor∘For at least 4 weeks before starting THALOMID oWhile∘While taking THALOMID oDuring∘During any breaks (interruptions) in your treatment with THALOMID oFor∘For at least 4 weeks after stopping THALOMID • Females who can become pregnant: oWill∘Will have pregnancy tests weekly for 4 weeks, then every 4 weeks if your menstrual cycle is regular, or every 2 weeks if your menstrual cycle is irregular. oIf∘If you miss your period or have unusual bleeding, you will need to have a pregnancy test and receive counseling. oMust∘Must agree to use two acceptable forms of birth control at the same time, for at least 4 weeks before, while taking, during any breaks (interruptions) in your treatment, and for at least 4 weeks after stopping THALOMID. oTalk∘Talk with your healthcare provider to find out about options for acceptable forms of birth control that you may use to prevent pregnancy before, during, and after treatment with THALOMID. oStop∘Stop taking THALOMID and call your healthcare provider right away if you have unprotected sex or if you think your birth control has failed. • If you become pregnant while taking THALOMID, stop taking it right away and call your healthcare provider. If your healthcare provider is not available, you should call the REMS Call Center at 1-888-423-5436. Healthcare providers and patients should report all cases of pregnancy to: oFDA∘FDA MedWatch at 1-800-FDA-1088, and oREMS∘REMS Call Center at 1-888-423-5436 There is a pregnancy exposure registry that monitors the outcomes of females who take THALOMID during pregnancy, or if their male partner takes THALOMID and they are exposed during pregnancy. You can enroll in this registry by calling the REMS Call Center at the phone number listed above. • THALOMID can pass into human semen: oMales∘Males, including those who have had a vasectomy, must always use a latex or synthetic condom during any sexual contact with a pregnant female or a female that can become pregnant while taking THALOMID, during any breaks (interruptions) in your treatment with THALOMID, and for up to 4 weeks after stopping THALOMID. oDo∘Do not have unprotected sexual contact with a female who is or could become pregnant. Tell your healthcare provider if you do have unprotected sexual contact with a female who is or could become pregnant. oDo∘Do not donate sperm while taking THALOMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping THALOMID. If a female becomes pregnant with your sperm, the baby may be exposed to THALOMID and may be born with birth defects. • Men, if your female partner becomes pregnant, you should call your healthcare provider right away. • Blood clots. People with multiple myeloma (MM) who take THALOMID may have an increased risk for blood clots in their arteries, veins, and lungs. This risk is even higher if you take the medicine dexamethasone with THALOMID to treat your MM. Heart attacks and strokes may also happen if you take THALOMID with dexamethasone. Before taking THALOMID, tell your healthcare provider about all the medicines you take. Certain other medicines can also increase your risk for blood clots. Call your healthcare provider or get medical help right away if you get any of the following during treatment with THALOMID: oSigns∘ Signs or symptoms of a blood clot in the lung, arm, or leg may include: shortness of breath, chest pain, or arm or leg swelling oSigns∘ Signs or symptoms of a heart attack may include: chest pain that may spread to the arms, neck, jaw, back, or stomach area (abdomen), feeling sweaty, shortness of breath, feeling sick or vomiting oSigns∘ Signs or symptoms of stroke may include: sudden numbness or weakness, especially on one side of the body, severe headache or confusion, or problems with vision, speech, or balance
What is THALOMID? THALOMID is a prescription medicine used: •to treat people who have been newly diagnosed with multiple myeloma (MM) in combination with the medicine dexamethasone. •to treat people who have moderate to severe new lesions of leprosy. THALOMID is not used by itself to treat the skin lesions when there is moderate to severe nerve pain. •as maintenance treatment to prevent and keep the skin lesions of leprosy from coming back (recurring). It is not known if THALOMID is safe and effective in children under 12 years of age.
1 unchanged line
What should I tell my healthcare provider before taking THALOMID? Before you take THALOMID, tell your healthcare provider about all of your medical conditions, including if you: •have a history of seizures •drink alcohol •plan to have surgery •are breastfeeding. THALOMID must not be used by females who are breastfeeding. It is not known if THALOMID passes into your breast milk and can harm your baby. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. THALOMID and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines. Certain medicines can affect the way that birth control pills, injections, transdermal systems (patches), or implants work. You could become pregnant. See "What is the most important information I should know about THALOMID?" Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.
How should I take THALOMID? •Take THALOMID exactly as prescribed and follow all the instructions of the THALOMIDThalidomide REMS program. •Keep THALOMID in the blister pack until you take your daily dose. •Swallow THALOMID capsules whole with water. •THALOMID is taken 1 time each day, at least 1 hour after your evening meal. Bedtime is the preferred time to take THALOMID. •Do not open or crush THALOMID capsules or handle them any more than needed. oIf∘If powder from the THALOMID capsule comes in contact with your skin, wash the skin right away with soap and water. oIf∘If powder from the THALOMID capsule comes in contact with the inside of your eyes, nose, and mouth, flush well with water. •If you miss a dose of THALOMID and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, just skip your missed dose. Do not take 2 doses at the same time. •If you take too much THALOMID, call your healthcare provider right away.
What should I avoid while taking THALOMID? •See "What is the most important information I should know about THALOMID?" • Females: Do not get pregnant and do not breastfeed while taking THALOMID. • Males: Do not donate sperm. • Do not share THALOMID with other people. It may cause birth defects and other serious problems. • Do not donate blood while you take THALOMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping THALOMID. If someone who is pregnant gets your donated blood, her baby may be exposed to THALOMID and may be born with birth defects. • THALOMID can cause drowsiness and sleepiness. Avoid drinking alcohol, operating machinery, and driving a car when taking THALOMID. Avoid taking other medicines that may cause drowsiness without talking to your healthcare provider first.
What are the possible side effects of THALOMID? THALOMID can cause serious side effects, including: •See "What is the most important information I should know about THALOMID?" • Drowsiness and sleepiness. See "What should I avoid while taking THALOMID?" • Nerve damage. Nerve damage is common with THALOMID. If the nerve damage is severe, it may not go away. Stop taking THALOMID and call your healthcare provider right away if you have any of these early symptoms of nerve damage in your hands, legs, or feet:
| onumbness | otingling | opain | oburning sensation
| ∘numbness | ∘tingling | ∘pain | ∘burning sensation
• Dizziness and decreased blood pressure when changing positions. THALOMID may cause a decrease in your blood pressure, and you may feel dizzy when you go from a lying down or sitting position to standing up. When changing positions, sit upright for a few minutes before standing to help prevent this. • Decreased white blood cell count. THALOMID can cause decreased white blood cell counts, including neutrophils. Neutrophils are a type of white blood cell that is important in fighting bacterial infections. Your healthcare provider should check your white blood count before and regularly while you take THALOMID. If your neutrophils are too low you should not start THALOMID and if they are low during treatment, your dose of THALOMID may need to be changed. • Decreased platelet count. THALOMID can cause decreased platelet counts. Your healthcare provider should check your platelet count before and regularly while you take THALOMID. If your platelets are too low, your healthcare provider may lower your dose, delay your dose, or completely stop treatment. Tell your healthcare provider if you have signs and symptoms of bleeding such as:
| osmall∘small red or purple spots on your body ounusual∘unusual bleeding or bruising onosebleeds∘nosebleeds | obright∘bright red or tar like stools ovomiting∘vomiting or coughing up blood
• Increased HIV virus in the blood. If you are HIV positive, your healthcare provider should check your viral load after one month and three months of treatment, then every 3 months after that. • Slow heartbeat (bradycardia). Tell your healthcare provider if you have a slow heartbeat, fainting, dizziness or shortness of breath. • Severe skin reactions and severe allergic reactions. Severe skin reactions and severe allergic reactions can happen with THALOMID and may cause death. Call your healthcare provider right away if you develop any of the following signs or symptoms during treatment with THALOMID:
| oa∘a red, itchy, skin rash opeeling∘peeling of your skin or blisters | osevere∘severe itching ofever∘fever
| Get emergency medical help right away if you develop any of the following signs or symptoms during treatment with THALOMID:
| oswelling∘swelling of your lips, mouth, tongue, or throat otrouble∘trouble breathing or swallowing | oraised∘raised red areas on your skin (hives) oa∘a very fast heartbeat oyou∘you feel dizzy or faint
• Seizures. Tell your healthcare provider right away if you have a seizure while taking THALOMID. • Tumor Lysis Syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure and sometimes death. Your healthcare provider may do blood tests to check you for TLS. • Birth control risks. Certain birth control methods may pose a higher risk of serious side effects and should not be used in some females. These risks include severe decreased white blood cell counts, low platelet counts, and blood clots. Use of an intrauterine device (IUD) or implantable birth control may also increase your risk of infection or bleeding during insertion, removal or during use of the device. Your healthcare provider may tell you to decrease your dose, temporarily stop or permanently stop taking THALOMID if you develop certain serious side effects during treatment with THALOMID.
4 unchanged lines
These are not all the possible side effects of THALOMID. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
How should I store THALOMID? •Store THALOMID at room temperature between 68°F to 77°F (20°C to 25°C). •Protect from light. •Return any unused THALOMID to THALOMIDThalidomide REMS by calling 1-888-423-53465436 or your healthcare provider. Keep THALOMID and all medicines out of the reach of children.
General information about the safe and effective use of THALOMID. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take THALOMID for conditions for which it was not prescribed. Do not give THALOMID to other people, even if they have the same symptoms you have. It may harm them and may cause birth defects. You can ask your healthcare provider or pharmacist for information about THALOMID that is written for health professionals. For more information, call 1-888-423-5436 or go to www.thalomidremsthalidomideremsprogram.com.
What are the ingredients in THALOMID? Active ingredient: thalidomide Inactive ingredients: pregelatinized starch and magnesium stearate. The 50 mg capsule shell contains gelatin, titanium dioxide and black ink. The 100 mg capsule shell contains black iron oxide, yellow iron oxide, titanium dioxide, gelatin, and black ink. The 150 mg capsule shell contains FD&C blue #2, black iron oxide, yellow iron oxide, titanium dioxide, gelatin, and black and white ink. The 200 mg capsule shell contains FD&C blue #2, titanium dioxide, gelatin, and white ink. Marketed by: Bristol-Myers Squibb Company, Princeton, NJ 08543 USA THALOMID® and THALOMID REMS®is area trademarkstrademark of Celgene Corporation, a Bristol-Myers Squibb company. THALPLYMG.027028 39/20232026

Untitled section

Changed5 words added, 7 removed
Marketed by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA
THALOMID® and THALOMID REMS®is area trademarkstrademark of Celgene Corporation, a Bristol-Myers Squibb company.
THALPLYPI.029030/MG.027028

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Drug interactions, Use in specific populations, Drug abuse and dependence, Overdosage, Nonclinical toxicology, References, Package label.

Every version

19 versions of set 2eda833b-1357-4ed4-a093-194524fcb061, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.